Key Points
- Grigorios Siokas, Cosmos Health's CEO, bought 156,190 shares on Jan 8 at $0.52 each for $81,218.80, raising his direct stake to 7,131,794 shares (a 2.24% increase) as part of multiple purchases since November.
- Despite the insider buying, Cosmos Health shows weak fundamentals — a $20.58M market cap, negative EPS and net margin (missed the last quarter's EPS), and a consensus analyst rating of Sell.
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 156,190 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The shares were acquired at an average cost of $0.52 per share, for a total transaction of $81,218.80. Following the purchase, the chief executive officer directly owned 7,131,794 shares in the company, valued at $3,708,532.88. This trade represents a 2.24% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Grigorios Siokas also recently made the following trade(s):
- On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.52 per share, with a total value of $64,937.60.
- On Tuesday, January 6th, Grigorios Siokas purchased 133,953 shares of Cosmos Health stock. The stock was acquired at an average price of $0.54 per share, with a total value of $72,334.62.
- On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.49 per share, for a total transaction of $43,273.86.
- On Monday, December 15th, Grigorios Siokas acquired 168,472 shares of Cosmos Health stock. The shares were acquired at an average price of $0.42 per share, for a total transaction of $70,758.24.
- On Friday, November 28th, Grigorios Siokas acquired 76,360 shares of Cosmos Health stock. The stock was acquired at an average price of $0.64 per share, with a total value of $48,870.40.
- On Tuesday, November 25th, Grigorios Siokas bought 55,732 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.63 per share, with a total value of $35,111.16.
- On Friday, November 21st, Grigorios Siokas bought 56,080 shares of Cosmos Health stock. The shares were bought at an average price of $0.68 per share, for a total transaction of $38,134.40.
- On Thursday, November 20th, Grigorios Siokas purchased 51,315 shares of Cosmos Health stock. The stock was bought at an average cost of $0.62 per share, for a total transaction of $31,815.30.
- On Wednesday, November 19th, Grigorios Siokas purchased 61,614 shares of Cosmos Health stock. The stock was bought at an average price of $0.65 per share, with a total value of $40,049.10.
Cosmos Health Stock Up 6.0%
Shares of COSM stock opened at $0.55 on Friday. The firm has a fifty day moving average of $0.57 and a 200-day moving average of $0.73. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25. Cosmos Health Inc. has a 12-month low of $0.28 and a 12-month high of $1.32. The company has a market capitalization of $20.58 million, a price-to-earnings ratio of -0.73 and a beta of 5.37.
Cosmos Health (NASDAQ:COSM - Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.16). The company had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. As a group, equities research analysts predict that Cosmos Health Inc. will post -0.78 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on COSM. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cosmos Health in a research report on Wednesday, October 8th. Wall Street Zen raised Cosmos Health to a "hold" rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Sell".
Check Out Our Latest Analysis on COSM
Hedge Funds Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC grew its stake in Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,507 shares of the company's stock after acquiring an additional 128,776 shares during the period. Citadel Advisors LLC owned 0.65% of Cosmos Health worth $250,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.61% of the company's stock.
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
